0
2023
Opioid Induced Constipation (oic) Drugs Market

Opioid Induced Constipation (OIC) Drugs Market

by Drug Type (Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, Others), by Prescription Type (Over The Counter Drugs, Prescribed Drugs), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Store and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A13376
Jan 2023 | Pages: 359
Tables: 127
Charts: 71
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Opioid Induced Constipation (OIC) Drugs Market Research, 2031

The global opioid induced constipation (OIC) drugs market was valued at $1105.71 million in 2021, and is projected to reach $1785.01 million by 2031, growing at a CAGR of 4.9% from 2022 to 2031. Opioid-induced constipation (OIC) is mainly caused by opioids which activate enteric -receptor, increasing tonic non propulsive contractions in the small and large intestines, increases colonic fluid absorption, and causes desiccation of stool. In addition, opioids are thought to raise the anal sphincter tone and the rectum's lowest sensory threshold, thus these combined actions lead to tougher stools as well as less frequent and ineffective defecation. The opioid induced constipation drugs market refers to the various drugs and treatments that are used to manage constipation caused by the use of opioids.

The COIVD-19 pandemic positively impacted to growth of opioid induced constipation drugs market, owing rise in number of patients suffering from chronic pain disorders, thus opioids were consumed for pain management. In addition, many people and geriatric population irrationally used opioids for pain management, owing to which rise in prevalence of constipation cases was observed. Further, opioid misuse increased during the pandemic as people experienced worsened mental health, more social isolation, greater job losses, and reduced access to treatment, which positively impacted to growth of opioid induced constipation (OIC) drugs market.

Opioid Induced Constipation (OIC) Drugs Market

“The opioid induced constipation drugs market size was positively impacted during the lockdown period owning to increase in sales of mu-opioid receptor antagonists and chloride channel activator. In addition, increase in demand for drugs in parenteral dosage form for treating opioid induced constipation (OIC) was observed as similar symptoms were experienced in COVID patients.”

Market Dynamics

Growth & innovations in the pharmaceutical industry for the manufacturing of opioid induced constipation (OIC) drugs owing to massive pool of health-conscious consumers, creates an opportunity for the opioid induced constipation drugs market share. The growth of the opioid induced constipation (OIC) drugs market is expected to be driven by emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of chronic pain cases in adults, and surge in demand for novel drugs for management of opioid induced constipation (OIC) disorder. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries. Various organizations along with government are counselling people regarding the opioid induced constipation (OIC). E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods.

Various animations through health apps to educate people regarding opioid induced constipation (OIC) and available treatment options have contributed towards the opioid induced constipation drugs market growth. The demand for effective medications for treating opioid induced constipation (OIC) is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the OIC drugs market size. Factors such as rise in adoption of methylnaltrexone (parenteral – subcutaneous) for opioid induced constipation (OIC) treatment, and increase in awareness toward use of mu-opioid receptor antagonists and chloride channel type-2 activator, further drive the growth of the OIC drugs market. Moreover, an increase in promotional activities by manufacturers and growth in awareness for proper treatment of opioid induced constipation (OIC) among the general population are expected to fuel their adoption in the near future.

However, side effects of the drug used in opioid induced constipation (OIC) drugs restrains the growth of opioid induced constipation (OIC) drugs market. In addition, high costs of novel pharmaceuticals and unfavorable reimbursement policies are probable factors which restrain the growth of market. In contrast, rising R&D activities, rise in regulatory approvals and higher spending for opioid induced constipation (OIC) research is expected to provide lucrative opportunities to key players of the market. In addition, rise in demand for novel therapeutics for treating opioid induced constipation (OIC) is further anticipated to drive the growth of the market.

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The COIVD-19 pandemic positively impacted to growth of opioid induced constipation drugs market, owing rise in number of patients suffering from chronic pain disorders, thus opioids were consumed for pain management. In addition, many people and geriatric population irrationally used opioids for pain management, owing to which rise in prevalence of constipation cases was observed. Further, opioid misuse increased during the pandemic as people experienced worsened mental health, more social isolation, greater job losses, and reduced access to treatment, which positively impacted to growth of opioid induced constipation (OIC) drugs market.

Segmental Overview

The opioid induced constipation (OIC) drugs market is segmented into drug type, route of administration, distribution channel and region. By Drug Type, the market is categorized into mu-opioid receptor antagonists, chloride channel-2 activators and others. By Prescription Type, the market is categorized into over the counter drugs and prescribed drugs. By Distribution Channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Opioid Induced Constipation (OIC) Drugs Market

By Drug Type

The market is categorized into mu-opioid receptor antagonists, chloride channel-2 activators and others. The mu-opioid receptor antagonists segment accounted for the largest share in 2021, and is also expected to remain dominant during the opioid induced constipation drugs market forecast period, to the rise in number of product launches by the key players for treating opioid induced constipation (OIC) and the rise in research activities for evaluating safety and efficacy of these agents.

Opioid Induced Constipation (OIC) Drugs Market

By Prescription Type

The market is categorized into over the counter drugs and prescribed drugs. The prescribed drugs segment occupied largest share in 2021 and is expected to remain dominant during forecast period owing to availability of major drugs and rise in number of key players manufacturing these formulations. The over the counter (OTC) drugs segment is projected to register highest CAGR during forecast period owing to rise in adoption of these drugs along with prescribed drugs for opioid induced constipation (OIC) management.

Opioid Induced Constipation (OIC) Drugs Market

By Distribution Channel

The market is categorized into hospital pharmacies, drug stores and retail pharmacies and online providers. The drug stores and retail pharmacies segment occupied largest share in 2021 and is expected to remain dominant during forecast period owing to increase in preference of the people toward retail pharmacies, as retail pharmacies guide regarding medications and usage during treatment period. The online providers segment is projected to register highest CAGR during forecast period owing to rise in popularity of online pharmacies and number of users preferring online pharmacies.

Opioid Induced Constipation (OIC) Drugs Market

By Region

The opioid induced constipation industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is expected to witness highest growth, in terms of revenue, owing rise in prevalence of opioid induced constipation (OIC) cases, prevalence of advanced healthcare infrastructure and increase in number of key players offering novel therapeutics, thereby driving the growth of the opioid induced constipation drugs market trends. Upsurge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion. However, Asia-Pacific is anticipated to witness notable growth, owing to increasing number of cancer cases resulting in rise in use of opioids, increase in awareness campaign and rise in investments for development of effective drugs for treating opioid induced constipation (OIC), thus, driving the growth of market during the forecast period.

Presence of several major players, such as AstraZeneca, Merck & Co., Shionogi & Co., Ltd., Mallinckrodt plc, Bausch Health Companies Inc., and advancement in manufacturing technology for development of effective medications for opioid induced constipation (OIC) treatment in the region drives the growth of the market. In addition, various private organizations organize educating camps across the globe marked the growth of this market. Furthermore, presence of well-established healthcare infrastructure, and rise in adoption rate of parenteral medication for opioid induced constipation (OIC) are expected to drive the market growth. Furthermore, various product approval and contract agreement as key strategy adopted by the key players in this region further boost the growth of the market. For instance, in April 2019, Sandoz (Novartis AG) signed an agreement with Shionogi & Co Ltd for commercialization of Rizmoic (naldemedine) in the key European markets of Germany, the UK and the Netherlands, plus right of first refusal for certain other European markets.

Asia-Pacific is expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to presence of key players in the region. Moreover, factors such as growing use of opioids for pain management, increasing geriatric population and rise in prevalence of cancer cases is anticipated to drive the growth of opioid induced constipation (OIC) drugs market. In India, increase in use of opioids for treating pain disorder is observed which results in prevalence of constipation, thus driving the growth of market. For instance, according to article published in National Library of Medicine 2020, stated that, in India, 2.1% of total population consumed opioids for pain management which accounts for three times the global average use, thus rise in opioid use results in higher chances of opioid induced constipation prevalence, thereby driving the growth of market. Further, in Japan, rise in prevalence of cancer cases is expected to drive the market growth. In addition, doctors prescribe opioids for cancer pain management, thus rise in use of opioids is expected to drive the market growth. For instance, according to article published in Japanese Journal of Clinical Oncology 2020, stated that, patients who received opioids for lung cancer pain management, had 59% prevalence rate for opioid induced constipation, thus driving the growth of market. Asia-Pacific offers profitable opportunities for key players operating in the opioid induced constipation (OIC) drugs market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising in spending for chronic pain disorders, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.

Competition Analysis

Competitive analysis and profiles of the major players in the opioid induced constipation (OIC) drugs market, such as AstraZeneca, Bausch Health Companies Inc., Cosmo pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Mallinckrodt plc, Merck & Co.,

Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shionogi & Co., Ltd. are provided in this report. Major players have adopted partnership, product approval and contract agreement as key developmental strategies to improve the product portfolio of the opioid induced constipation (OIC) drugs market.

Some Examples Of Agreement In The Market

In February 2021, Cosmo Pharmaceuticals announced an agreement with RedHill Biopharma Ltd. for manufacturing of Movantik designed to treat opioid-induced constipation (OIC) in adult patients.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid induced constipation drugs market analysis from 2021 to 2031 to identify the prevailing opioid induced constipation drugs market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the opioid induced constipation (OIC) drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global opioid induced constipation (OIC) drugs market trends, key players, market segments, application areas, and market growth strategies.

Opioid Induced Constipation (OIC) Drugs Market Report Highlights

Aspects Details
Market Size By 2031 USD 1.8 billion
Growth Rate CAGR of 4.9%
Forecast period 2021 - 2031
Report Pages 359
By Drug Type
  • Mu-opioid Receptor Antagonists
  • Chloride Channel-2 Activators
  • Others
By Prescription Type
  • Over The Counter Drugs
  • Prescribed Drugs
By Distribution Channel
  • Hospital Pharmacies
  • Online Providers
  • Drug Store and Retail Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., cosmo pharmaceuticals, Mallinckrodt plc, Dr. Reddy’s Laboratories Ltd., Shionogi & Co., Ltd., Merck & Co., Inc.
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Bargaining power of suppliers

      • 3.3.2. Bargaining power of buyers

      • 3.3.3. Threat of substitutes

      • 3.3.4. Threat of new entrants

      • 3.3.5. Intensity of rivalry

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Rise in prevalence of opioid induced constipation (OIC) cases
        • 3.4.1.2. Rise in administration of opioids for cancer and non-cancer pain
        • 3.4.1.3. Rise in the availability of effective opioid induced constipation (OIC) drugs

      • 3.4.2. Restraints

        • 3.4.2.1. Side effects associated with medications used for opioid induced constipation

      • 3.4.3. Opportunities

        • 3.4.3.1. Growth opportunities in emerging markets

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Mu-opioid Receptor Antagonists

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Chloride Channel-2 Activators

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

    • 4.4. Others

      • 4.4.1. Key market trends, growth factors and opportunities

      • 4.4.2. Market size and forecast, by region

      • 4.4.3. Market share analysis by country

  • CHAPTER 5: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Over The Counter Drugs

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Prescribed Drugs

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

  • CHAPTER 6: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Hospital Pharmacies

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Online Providers

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

    • 6.4. Drug Store and Retail Pharmacies

      • 6.4.1. Key market trends, growth factors and opportunities

      • 6.4.2. Market size and forecast, by region

      • 6.4.3. Market share analysis by country

  • CHAPTER 7: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Drug Type

      • 7.2.3. Market size and forecast, by Prescription Type

      • 7.2.4. Market size and forecast, by Distribution Channel

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Drug Type
          • 7.2.5.1.3. Market size and forecast, by Prescription Type
          • 7.2.5.1.4. Market size and forecast, by Distribution Channel
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Drug Type
          • 7.2.5.2.3. Market size and forecast, by Prescription Type
          • 7.2.5.2.4. Market size and forecast, by Distribution Channel
        • 7.2.5.3. Mexico
          • 7.2.5.3.1. Key market trends, growth factors and opportunities
          • 7.2.5.3.2. Market size and forecast, by Drug Type
          • 7.2.5.3.3. Market size and forecast, by Prescription Type
          • 7.2.5.3.4. Market size and forecast, by Distribution Channel
    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Drug Type

      • 7.3.3. Market size and forecast, by Prescription Type

      • 7.3.4. Market size and forecast, by Distribution Channel

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Drug Type
          • 7.3.5.1.3. Market size and forecast, by Prescription Type
          • 7.3.5.1.4. Market size and forecast, by Distribution Channel
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Drug Type
          • 7.3.5.2.3. Market size and forecast, by Prescription Type
          • 7.3.5.2.4. Market size and forecast, by Distribution Channel
        • 7.3.5.3. UK
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Drug Type
          • 7.3.5.3.3. Market size and forecast, by Prescription Type
          • 7.3.5.3.4. Market size and forecast, by Distribution Channel
        • 7.3.5.4. Italy
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Drug Type
          • 7.3.5.4.3. Market size and forecast, by Prescription Type
          • 7.3.5.4.4. Market size and forecast, by Distribution Channel
        • 7.3.5.5. Spain
          • 7.3.5.5.1. Key market trends, growth factors and opportunities
          • 7.3.5.5.2. Market size and forecast, by Drug Type
          • 7.3.5.5.3. Market size and forecast, by Prescription Type
          • 7.3.5.5.4. Market size and forecast, by Distribution Channel
        • 7.3.5.6. Rest of Europe
          • 7.3.5.6.1. Key market trends, growth factors and opportunities
          • 7.3.5.6.2. Market size and forecast, by Drug Type
          • 7.3.5.6.3. Market size and forecast, by Prescription Type
          • 7.3.5.6.4. Market size and forecast, by Distribution Channel
    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Drug Type

      • 7.4.3. Market size and forecast, by Prescription Type

      • 7.4.4. Market size and forecast, by Distribution Channel

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. Japan
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Drug Type
          • 7.4.5.1.3. Market size and forecast, by Prescription Type
          • 7.4.5.1.4. Market size and forecast, by Distribution Channel
        • 7.4.5.2. China
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Drug Type
          • 7.4.5.2.3. Market size and forecast, by Prescription Type
          • 7.4.5.2.4. Market size and forecast, by Distribution Channel
        • 7.4.5.3. Australia
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Drug Type
          • 7.4.5.3.3. Market size and forecast, by Prescription Type
          • 7.4.5.3.4. Market size and forecast, by Distribution Channel
        • 7.4.5.4. India
          • 7.4.5.4.1. Key market trends, growth factors and opportunities
          • 7.4.5.4.2. Market size and forecast, by Drug Type
          • 7.4.5.4.3. Market size and forecast, by Prescription Type
          • 7.4.5.4.4. Market size and forecast, by Distribution Channel
        • 7.4.5.5. South Korea
          • 7.4.5.5.1. Key market trends, growth factors and opportunities
          • 7.4.5.5.2. Market size and forecast, by Drug Type
          • 7.4.5.5.3. Market size and forecast, by Prescription Type
          • 7.4.5.5.4. Market size and forecast, by Distribution Channel
        • 7.4.5.6. Rest of Asia-Pacific
          • 7.4.5.6.1. Key market trends, growth factors and opportunities
          • 7.4.5.6.2. Market size and forecast, by Drug Type
          • 7.4.5.6.3. Market size and forecast, by Prescription Type
          • 7.4.5.6.4. Market size and forecast, by Distribution Channel
    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Drug Type

      • 7.5.3. Market size and forecast, by Prescription Type

      • 7.5.4. Market size and forecast, by Distribution Channel

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Brazil
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Drug Type
          • 7.5.5.1.3. Market size and forecast, by Prescription Type
          • 7.5.5.1.4. Market size and forecast, by Distribution Channel
        • 7.5.5.2. Saudi Arabia
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Drug Type
          • 7.5.5.2.3. Market size and forecast, by Prescription Type
          • 7.5.5.2.4. Market size and forecast, by Distribution Channel
        • 7.5.5.3. South Africa
          • 7.5.5.3.1. Key market trends, growth factors and opportunities
          • 7.5.5.3.2. Market size and forecast, by Drug Type
          • 7.5.5.3.3. Market size and forecast, by Prescription Type
          • 7.5.5.3.4. Market size and forecast, by Distribution Channel
        • 7.5.5.4. Rest of LAMEA
          • 7.5.5.4.1. Key market trends, growth factors and opportunities
          • 7.5.5.4.2. Market size and forecast, by Drug Type
          • 7.5.5.4.3. Market size and forecast, by Prescription Type
          • 7.5.5.4.4. Market size and forecast, by Distribution Channel
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2021

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. AstraZeneca plc

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

      • 9.1.6. Business performance

    • 9.2. Bausch Health Companies Inc.

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

      • 9.2.6. Business performance

    • 9.3. cosmo pharmaceuticals

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

      • 9.3.6. Business performance

      • 9.3.7. Key strategic moves and developments

    • 9.4. Dr. Reddy’s Laboratories Ltd.

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

      • 9.4.6. Business performance

    • 9.5. Mallinckrodt plc

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

      • 9.5.6. Business performance

    • 9.6. Merck & Co., Inc.

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

      • 9.6.6. Business performance

    • 9.7. Novartis AG

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

      • 9.7.6. Business performance

      • 9.7.7. Key strategic moves and developments

    • 9.8. Shionogi & Co., Ltd.

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

      • 9.8.6. Business performance

    • 9.9. Takeda Pharmaceutical Company Limited

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

    • 9.10. Teva Pharmaceutical Industries Ltd.

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

      • 9.10.6. Business performance

  • LIST OF TABLES

  • TABLE 01. GLOBAL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 02. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 03. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR CHLORIDE CHANNEL-2 ACTIVATORS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 04. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 05. GLOBAL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 06. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 07. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR PRESCRIBED DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 08. GLOBAL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 09. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 10. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 11. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 12. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 13. NORTH AMERICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 14. NORTH AMERICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 15. NORTH AMERICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 16. NORTH AMERICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 17. U.S. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 18. U.S. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 19. U.S. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 20. CANADA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 21. CANADA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 22. CANADA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 23. MEXICO OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 24. MEXICO OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 25. MEXICO OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 26. EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 27. EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 28. EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 29. EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 30. GERMANY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 31. GERMANY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 32. GERMANY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 33. FRANCE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 34. FRANCE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 35. FRANCE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 36. UK OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 37. UK OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 38. UK OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 39. ITALY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 40. ITALY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 41. ITALY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 42. SPAIN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 43. SPAIN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 44. SPAIN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 45. REST OF EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 46. REST OF EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 47. REST OF EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 48. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 49. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 50. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 51. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 52. JAPAN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 53. JAPAN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 54. JAPAN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 55. CHINA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 56. CHINA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 57. CHINA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 58. AUSTRALIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 59. AUSTRALIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 60. AUSTRALIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 61. INDIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 62. INDIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 63. INDIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 64. SOUTH KOREA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 65. SOUTH KOREA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 66. SOUTH KOREA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 67. REST OF ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 68. REST OF ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 69. REST OF ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 70. LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 71. LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 72. LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 73. LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 74. BRAZIL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 75. BRAZIL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 76. BRAZIL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 77. SAUDI ARABIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 78. SAUDI ARABIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 79. SAUDI ARABIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 80. SOUTH AFRICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 81. SOUTH AFRICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 82. SOUTH AFRICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 83. REST OF LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 84. REST OF LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 85. REST OF LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 86. ASTRAZENECA PLC: KEY EXECUTIVES
    TABLE 87. ASTRAZENECA PLC: COMPANY SNAPSHOT
    TABLE 88. ASTRAZENECA PLC: PRODUCT SEGMENTS
    TABLE 89. ASTRAZENECA PLC: PRODUCT PORTFOLIO
    TABLE 90. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
    TABLE 91. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
    TABLE 92. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
    TABLE 93. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
    TABLE 94. COSMO PHARMACEUTICALS: KEY EXECUTIVES
    TABLE 95. COSMO PHARMACEUTICALS: COMPANY SNAPSHOT
    TABLE 96. COSMO PHARMACEUTICALS: PRODUCT SEGMENTS
    TABLE 97. COSMO PHARMACEUTICALS: PRODUCT PORTFOLIO
    TABLE 98. COSMO PHARMACEUTICALS: KEY STRATERGIES
    TABLE 99. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
    TABLE 100. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
    TABLE 101. DR. REDDY’S LABORATORIES LTD.: PRODUCT SEGMENTS
    TABLE 102. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
    TABLE 103. MALLINCKRODT PLC: KEY EXECUTIVES
    TABLE 104. MALLINCKRODT PLC: COMPANY SNAPSHOT
    TABLE 105. MALLINCKRODT PLC: PRODUCT SEGMENTS
    TABLE 106. MALLINCKRODT PLC: PRODUCT PORTFOLIO
    TABLE 107. MERCK & CO., INC.: KEY EXECUTIVES
    TABLE 108. MERCK & CO., INC.: COMPANY SNAPSHOT
    TABLE 109. MERCK & CO., INC.: PRODUCT SEGMENTS
    TABLE 110. MERCK & CO., INC.: PRODUCT PORTFOLIO
    TABLE 111. NOVARTIS AG: KEY EXECUTIVES
    TABLE 112. NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 113. NOVARTIS AG: PRODUCT SEGMENTS
    TABLE 114. NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 115. NOVARTIS AG: KEY STRATERGIES
    TABLE 116. SHIONOGI & CO., LTD.: KEY EXECUTIVES
    TABLE 117. SHIONOGI & CO., LTD.: COMPANY SNAPSHOT
    TABLE 118. SHIONOGI & CO., LTD.: PRODUCT SEGMENTS
    TABLE 119. SHIONOGI & CO., LTD.: PRODUCT PORTFOLIO
    TABLE 120. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
    TABLE 121. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
    TABLE 122. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
    TABLE 123. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
    TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
    TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
    TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
    TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • LIST OF FIGURES

  • FIGURE 01. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031
    FIGURE 02. SEGMENTATION OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031
    FIGURE 03. TOP INVESTMENT POCKETS IN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET (2022-2031)
    FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
    FIGURE 05. LOW BARGAINING POWER OF BUYERS
    FIGURE 06. LOW THREAT OF SUBSTITUTES
    FIGURE 07. LOW THREAT OF NEW ENTRANTS
    FIGURE 08. LOW INTENSITY OF RIVALRY
    FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALOPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET
    FIGURE 10. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021(%)
    FIGURE 11. COMPARATIVE SHARE ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR MU-OPIOID RECEPTOR ANTAGONISTS, BY COUNTRY 2021-2031(%)
    FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR CHLORIDE CHANNEL-2 ACTIVATORS, BY COUNTRY 2021-2031(%)
    FIGURE 13. COMPARATIVE SHARE ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
    FIGURE 14. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021(%)
    FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY COUNTRY 2021-2031(%)
    FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR PRESCRIBED DRUGS, BY COUNTRY 2021-2031(%)
    FIGURE 17. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
    FIGURE 18. COMPARATIVE SHARE ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
    FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
    FIGURE 20. COMPARATIVE SHARE ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
    FIGURE 21. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET BY REGION, 2021
    FIGURE 22. U.S. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 23. CANADA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 24. MEXICO OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 25. GERMANY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 26. FRANCE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 27. UK OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 28. ITALY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 29. SPAIN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 30. REST OF EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 31. JAPAN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 32. CHINA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 33. AUSTRALIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 34. INDIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 35. SOUTH KOREA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 36. REST OF ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 37. BRAZIL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 38. SAUDI ARABIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 39. SOUTH AFRICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 40. REST OF LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 45. COMPETITIVE DASHBOARD
    FIGURE 46. COMPETITIVE HEATMAP: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET
    FIGURE 47. TOP PLAYER POSITIONING, 2021
    FIGURE 48. ASTRAZENECA PLC: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 49. ASTRAZENECA PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 50. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 51. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 52. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 53. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 54. COSMO PHARMACEUTICALS: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 55. DR. REDDY’S LABORATORIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 56. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 57. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 58. MALLINCKRODT PLC: NET SALES, 2019-2021 ($MILLION)
    FIGURE 59. MALLINCKRODT PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 60. MALLINCKRODT PLC: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 61. MERCK & CO., INC.: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 62. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 63. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 64. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
    FIGURE 65. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 66. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 67. SHIONOGI & CO., LTD.: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 68. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 69. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 70. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 71. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)

 
 

This section provides various opinions of top-level CXOs in the global opioid induced constipation (OIC) drugs market. According to the insights of CXOs, increase in demand for advanced therapeutics and rise in investments for R & D activities related to opioid induced constipation (OIC) globally, is expected to offer lucrative opportunities to key players of the market. In addition, favorable government initiatives and higher spending for opioid induced constipation (OIC), has piqued the interest of several companies to develop novel medications.

CXOs further added that rising expenditure on the development of healthcare infrastructure and surge in prevalence of opioid induced constipation (OIC) cases is expected to boost the growth of opioid induced constipation (OIC) drugs market. In addition, increasing chronic pain disorders such as cancer, back pain across the globe has resulted in rise in use of opioids leading to chances of occurrence of constipation, thus driving the growth of market. Further, geriatric people are prone to various chronic pain disorders, thus rise in geriatric populations is also fostering the growth of the opioid induced constipation drug market.

Furthermore, North America is expected to witness highest growth, in terms of revenue, owing rise in prevalence of opioid induced constipation cases and increase in number of key players offering novel therapeutics to treat opioid induced constipation (OIC), thus driving the growth of opioid induced constipation (OIC) market. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in pain disorders, increase in awareness campaign and rise in investments for development of effective drugs for treating opioid induced constipation (OIC), which is expected to drive the growth of market during the forecast period.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The major factor that fuels the growth of the opioid induced constipation (OIC) drugs market are rise in prevalence of opioid induced constipation (OIC) cases, prevalence of advanced healthcare infrastructure and increase in number of key players offering novel therapeutics.

A. Cancer is the leading application of Opioid Induced Constipation (OIC) Drugs Market.

A. North America is the largest regional market for Opioid Induced Constipation (OIC) Drugs.

A. The total market value of opioid induced constipation (OIC) drugs market is $1105.71 million in 2021.

A. Top companies such as, AstraZeneca plc, Shionogi & Co., Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc. and Novartis AG held a high market position in 2021. These key players held a high market position owing to the strong geographical foothold in North America, Europe, Asia-Pacific, and LAMEA.

A. The forecast period for opioid induced constipation (OIC) drugs market is 2022 to 2031.

A. The base year is 2021 in opioid induced constipation (OIC) drugs market.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Opioid Induced Constipation (oic) Drugs Market

Start reading instantly.
This Report and over 67,132+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers